Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Alfred E Tiefenbacher GmbH.

    Client Virtual Booth

    ALFRED E TIEFENBACHER GMBH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Tiefenbacher Group
    Alfred E Tiefenbacher GmbH
    Germany Flag
    Country
    Country
    Germany
    Address
    Address
    Van-der-Smissen-Strasse 1, 22767 Hamburg
    Telephone
    Telephone
    +49 404418090
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://aet.eu/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/alfred-e.-tiefenbacher-gmbh-&-co.-kg-/
    Twitter
    Twitter
    Contact Info
    Others

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tiefenbacher Pharmaceuticals Successfully Prepares the Launch of The Anticoagulant Rivaroxaban.

    Details:

    Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.


    Lead Product(s): Rivaroxaban

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 09, 2024

    Tiefenbacher Compnay Banner

    Arab Pharma Expo 2024

    Not Confirmed

    envelop Contact Supplier
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tiefenbacher Pharmaceuticals Successfully Launches the Anticoagulant Rivaroxaban on Day One in Canada

    Details:

    Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.


    Lead Product(s): Rivaroxaban

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 16, 2023

    Tiefenbacher Compnay Banner

    Arab Pharma Expo 2024

    Not Confirmed

    envelop Contact Supplier
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tiefenbacher Pharmaceuticals Successfully Launches the Generic Version of Teriflunomide in more than 20 European Countries

    Details:

    Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.


    Lead Product(s): Teriflunomide

    Therapeutic Area: Neurology Product Name: Aubagio-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 27, 2023

    Tiefenbacher Compnay Banner

    Arab Pharma Expo 2024

    Not Confirmed

    envelop Contact Supplier
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tiefenbacher Pharmaceuticals Successfully Launches the Antihistamine Bilastine for A Market Entry as Over-the-counter (OTC) Medicine in Germany

    Details:

    Bilastine Tiefenbacher (Bilastine) is a histamine H1 receptor inverse agonist, small molecule drug candidate which is indicated for the treatment of allergic rhino-conjunctivitis & urticaria.


    Lead Product(s): Bilastine

    Therapeutic Area: Immunology Product Name: Bilastine Tiefenbacher

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 14, 2023

    Tiefenbacher Compnay Banner

    Arab Pharma Expo 2024

    Not Confirmed

    envelop Contact Supplier
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tiefenbacher Pharmaceuticals Successfully Launches Generic Version of The Psoriasis Medication Apremilast in Canada

    Details:

    Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers.


    Lead Product(s): Apremilast

    Therapeutic Area: Dermatology Product Name: Otezla-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 01, 2022

    Tiefenbacher Compnay Banner

    Arab Pharma Expo 2024

    Not Confirmed

    envelop Contact Supplier
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches Generic Versions of The Prostate Cancer Medicines Abiraterone and Abiraterone/pred...

    Details:

    Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.


    Lead Product(s): Abiraterone Acetate,Prednisolone

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 17, 2022

    Tiefenbacher Compnay Banner

    Arab Pharma Expo 2024

    Not Confirmed

    envelop Contact Supplier
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tiefenbacher Pharmaceuticals Successfully Launches Generic Version of The Anticoagulant Medicine Apixaban in Canada

    Details:

    Apixaban Tiefenbacher (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.


    Lead Product(s): Apixaban

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Apixaban Tiefenbacher

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 20, 2022

    Tiefenbacher Compnay Banner

    Arab Pharma Expo 2024

    Not Confirmed

    envelop Contact Supplier
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tiefenbacher Pharmaceuticals Successfully Launches Generic Version of The Diabetes Medicine Vildagliptin and Vildagliptin /metformin in Africa

    Details:

    Vildagliptin/Metformin generic version launched in Africa market, the drug ais a diabetes medicine that are used to control the blood glucose (sugar) in adults with type 2 diabetes, by inhibiting DPP-4.


    Lead Product(s): Vildagliptin,Metformin

    Therapeutic Area: Endocrinology Product Name: Vildagliptin-Metformin-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 08, 2022

    Tiefenbacher Compnay Banner

    Arab Pharma Expo 2024

    Not Confirmed

    envelop Contact Supplier
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Tiefenbacher Pharmaceuticals Expands the Launch of The Anticoagulant Medicine Rivaroxaban to Central America and Further International Markets

    Details:

    Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.


    Lead Product(s): Rivaroxaban

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 15, 2022

    Tiefenbacher Compnay Banner

    Arab Pharma Expo 2024

    Not Confirmed

    envelop Contact Supplier
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Multiple Sclerosis Medicine Teriflunomide in Canada

    Details:

    Teriflunomide is a pyrimidine synthesis inhibitor with anti-inflammatory and immunomodulatory properties used to treat patients with the relapsing-remitting form of multiple sclerosis.


    Lead Product(s): Teriflunomide

    Therapeutic Area: Immunology Product Name: Teriflunomide-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 01, 2022

    Tiefenbacher Compnay Banner

    Arab Pharma Expo 2024

    Not Confirmed

    envelop Contact Supplier
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Access Website

    Contact Supplier

    View Presentation

    Tiefenbacher Group

    CPhI Worldwide, Milan

    Booth #24A21

    envelop Contact Supplier

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search